LianBio
LIANY evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for LIANY—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · LIANY
LianBio is a biotechnology company focused on in-licensing and developing therapeutic candidates for Greater China and other Asian markets, with a pipeline spanning cardiovascular, oncology, ophthalmology, and inflammation indications.
Key risk: Operating losses
BioSniper Score
Based on 4 of 6 signals
Financial data as of Sep 30, 2023.
Tracking 3 pipeline candidates · 1 clinical trial for LianBio.
LianBio is a biotechnology company focused on in-licensing and developing therapeutic candidates for Greater China and other Asian markets, with a pipeline spanning cardiovascular, oncology, ophthalmology, and inflammation indications.
- LianBio has a pipeline of seven therapeutic candidates across oncology, ophthalmology, and inflammation indications as of 2023-11-13 [sec_mda].
- The company reported cash and equivalents of $103.5M as of 2023-09-30 [sec].
- Net income was -$24.0M for the period ending 2023-09-30 [sec].
- Shareholders' equity stood at $272.8M as of 2023-09-30 [sec].
- In August 2023, the first patient was treated in a Phase 1 trial of BBP-398 in combination with osimertinib in Chinese NSCLC patients with EGFR mutations [sec_mda].
What works
- LianBio has built a cross-border platform to provide licensing partners access to regulatory, development, and commercial expertise in China and other Asian markets [sec_mda · as of 2023-11-13].
- The company has a diverse portfolio of highly differentiated assets across multiple therapeutic areas, representing significant potential market opportunity [sec_mda · as of 2023-08-14].
- LianBio completed enrollment in the Phase 3 EXPLORER-CN trial for mavacamten in Chinese patients with obstructive hypertrophic cardiomyopathy in August 2022, with topline results expected in mid-2023 [sec_mda · as of 2022-11-10].
What to weigh
- LianBio reported a net loss of $24.0M for the period ending 2023-09-30, indicating ongoing operating losses [sec].
- The company's pipeline is dependent on in-licensed candidates, which carries risks related to licensing agreements and partner dependencies [sec_mda · as of 2023-11-13].
- The COVID-19 pandemic caused delays in clinical trial enrollment, potentially impacting development timelines [sec_mda · as of 2023-08-14].
From the filings
Quoted directly from source documents.
LianBio's pipeline includes seven therapeutic candidates as of November 2023.
“We have a pipeline of seven therapeutic candidates across oncology, ophthalmology and inflammation indications”
SEC MD&A · November 13, 2023
First patient treated in Phase 1 trial of BBP-398 in combination with osimertinib in August 2023.
“In August 2023, we announced that the first patient was treated in the Phase 1 trial of BBP-398 in combination with osimertinib in Chinese NSCLC patients with EGFR mutations.”
SEC MD&A · August 14, 2023
Enrollment completed in Phase 3 EXPLORER-CN trial for mavacamten in August 2022.
“In August 2022, we announced that enrollment was completed in the Phase 3 EXPLORER-CN clinical trial in Chinese patients with obstructive hypertrophic cardiomyopathy.”
SEC MD&A · November 10, 2022
Risks & what to watch (3)›
Key risks
- Operating losses — Net loss of $24.0M for the period ending 2023-09-30, indicating ongoing cash burn [sec].
- Dependence on in-licensed assets — Pipeline relies on licensing partners, exposing the company to risks from partner decisions and contract terms [sec_mda].
- Clinical trial delays — COVID-19 pandemic caused enrollment delays, potentially affecting development timelines [sec_mda].
What to watch
- Topline results from the Phase 3 EXPLORER-CN trial for mavacamten, expected in mid-2023 [sec_mda].
- Progress of the Phase 1 trial of BBP-398 in combination with osimertinib in Chinese NSCLC patients [sec_mda].
- Updates on pipeline expansion or new licensing agreements in Greater China and other Asian markets [sec_mda].
Sources: SEC filings · SEC MD&A · Generated August 15, 2026 · How we verify sources →
Run LianBio through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available LianBio facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
46.6 months
D/E 0.13 · 0% dilution
Lead: Phase 3
3 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Pipeline
Regulatory
Financials
Short Interest
as of Apr 30, 2026- % of float
- 0.8%
- Days to cover
- 0.4
- Shares short
- 378,131
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
LIANY short interestGovernance
Frequently asked questions
What is the AI investment thesis for LianBio?
LianBio is a biotechnology company focused on in-licensing and developing therapeutic candidates for Greater China and other Asian markets, with a pipeline spanning cardiovascular, oncology, ophthalmology, and inflammation indications.
What is LianBio's lead drug candidate?
LianBio's most advanced tracked candidate is infigratinib (Phase 2) for gastric cancer and other FGFR-driven tumors.
Who is the CEO of LianBio?
Mr. Adam Leo Stone is the chief executive officer of LianBio (LIANY).
Where is LianBio headquartered?
LianBio (LIANY) is headquartered in Princeton, NJ, United States.
What therapeutic areas does LianBio focus on?
LianBio develops therapies across Oncology, Dermatology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.